NIBR-17
| Code | Size | Price |
|---|
| SYN-1145-M100 | 100 mg | Enquire |
Quantity:
| SYN-1145-M001 | 1 mg | £209.00 |
Quantity:
| SYN-1145-M005 | 5 mg | £256.00 |
Quantity:
| SYN-1145-M010 | 10 mg | £438.00 |
Quantity:
| SYN-1145-M050 | 50 mg | £1,146.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
NIBR17
Appearance:
Solid.
CAS:
944396-88-7
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C18H20N8O2/c1-27-16-3-2-13(11-20-16)23-15-8-14(12-9-21-17(19)22-10-12)24-18(25-15)26-4-6-28-7-5-26/h2-3,8-11H,4-7H2,1H3,(H2,19,21,22)(H,23,24,25)
InChiKey:
XZTYTIOLZIKUJR-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 944396-88-7. Formula: C18H20N8O2. MW: 380.4. NIBR-17 is a pan class I PI3K inhibitor with IC(50) values of 1, 9.2, 9 and 20nM, respectively for PI3Kalpha - delta.
Molecular Formula:
C18H20N8O2
Molecular Weight:
380.4
Package Type:
Plastic Vial
Product Description:
NIBR-17 is a pan class I PI3K inhibitor with IC(50) values of 1, 9.2, 9 and 20nM, respectively for PI3Kalpha - delta.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors: M.T. Burger, et al.; ACS Med. Chem. Lett. 2, 34 (2010)
Related Products
| Product Name | Product Code | Supplier | LY-294002 | AG-CR1-0108 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|